Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS

Submitted by centretek on Sat, 10/15/2022 - 10:29
Source URL
https://www.inova.org/clinical-trials/optimizing-smoking-cessation-treatments-smokers-living-hivaids
Description
General Information Age Group Adults Status Recruiting Protocol Number HP-00062925 Background Information This is a research study for smoking patients living with HIV who are looking to quit smoking. The study will provide Chantix or a placebo to enrolled patients for 3 months. The study will be randomized, so the patient and study team will not know which patient will receive Chantix or the placebo. Half of the enrolled patient will also receive counseling intervention for smoking cessation, called Positively Smoke Free (PSF) program. The intervention will also be randomized and patients will not know whether they will receive the PSF intervention until the Baseline visit. This study will collect blood samples at three different time points, approximately 10 teaspoons of blood at each time point. A carbon monoxide breath test will also be conducted at each study visit. The study will last approximately 7 months; the treatment period will last approximately 3 months, with a follow up visit 3 months after the end of treatment. Offered At Inova Fairfax Hospital 3300 Gallows Road Falls Church, VA 22042 Principal Investigator Christopher deFilippi, MD Eligibility Information Confirmed chart diagnosis of HIV and receiving HIV treatment at the participating HIV clinic Age 18 years or older Currently self-reporting smoking, approximately 10 cigarettes per day Motivation to quit smoking Does not meet current DSM 5 criteria for alcohol or substance use disorder Able to read and speak English Willingness and ability to provide informed consent to participate Ineligibility Information Recent use of Chantix (varenicline) Allergic reaction or sensitivity to Chantix (varenciline) Pregnant, nursing, or plans to become pregnant during the study Moderate to severe renal impairment Unstable cardiovascular disease; determined by physician, chart review, and EKG Score of <5ppm on carbon monoxide breath test Study physician will determine overall eligibility if all eligibility criteria are met, and ineligibility criteria are not met Contact Information Contact Name Salman Baig Contact Phone 703-776-4182 Contact Email Send Email Contact Information Contact Name Katherine Armstrong Contact Phone 571-472-2918 Contact Email Send Email Contact Information Contact Name Jane Lettman Contact Phone 571-472-2915 Contact Email Send Email
Clinical Trials Sub categories
Infectious Disease
Crawled Content Type
Clinical Trials
Age Group
Adults
is_synonym
Off
Also a children's page
Off